A Prospective, Randomized, Double-Blind Parallel-group, Non-inferiority Phase II/III Study of the Safety and Effectiveness of BPL HRIG With Co Administration of Active Rabies Vaccine in Healthy Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Human-rabies-immunoglobulin-vaccine-Bio-Products-Laboratory (Primary) ; Rabies vaccine
- Indications Rabies
- Focus Therapeutic Use
- Sponsors Bio Products Laboratory
- 25 Oct 2019 Planned End Date changed from 13 Jul 2019 to 31 Oct 2019.
- 15 Mar 2019 Planned End Date changed from 1 Feb 2019 to 13 Jul 2019.
- 16 Jul 2018 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.